Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Matinas Biopharma Holdings, Inc. (MTNB : AMEX)
 
 • Company Description   
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.

Number of Employees: 2

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.70 Daily Weekly Monthly
20 Day Moving Average: 359,998 shares
Shares Outstanding: 6.41 (millions)
Market Capitalization: $4.51 (millions)
Beta: 1.61
52 Week High: $3.09
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 14.12% 8.54%
12 Week 17.06% 8.21%
Year To Date 20.15% 5.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1545 ROUTE 206 SOUTH SUITE 302
-
BEDMINSTER,NJ 07921
USA		 ph: 908-484-8805
fax: -		 info@matinasbiopharma.com http://www.matinasbiopharma.com
 
 • General Corporate Information   
Officers
Jerome D. Jabbour - Chairman; Chief Executive Officer; President & Int
Evelyn D'An - Director
Keith Murphy - Director
Edward Neugeboren - Director
Robin L. Smith - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 576810303
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/13/26
Share - Related Items
Shares Outstanding: 6.41
Most Recent Split Date: 9.00 (0.02:1)
Beta: 1.61
Market Capitalization: $4.51 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/13/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.49
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 9.09%
vs. Previous Quarter: -15.38%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/26 - -193.02
12/31/25 - -163.98
09/30/25 - -240.99
ROA
03/31/26 - -124.09
12/31/25 - -102.52
09/30/25 - -147.32
Current Ratio
03/31/26 - 1.32
12/31/25 - 2.79
09/30/25 - 3.78
Quick Ratio
03/31/26 - 1.32
12/31/25 - 2.79
09/30/25 - 3.78
Operating Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Net Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Pre-Tax Margin
03/31/26 - -
12/31/25 - -
09/30/25 - -
Book Value
03/31/26 - 0.47
12/31/25 - 0.75
09/30/25 - 1.27
Inventory Turnover
03/31/26 - -
12/31/25 - -
09/30/25 - -
Debt-to-Equity
03/31/26 - 0.00
12/31/25 - 0.00
09/30/25 - 0.00
Debt-to-Capital
03/31/26 - 0.17
12/31/25 - 0.10
09/30/25 - 0.17
 

Powered by Zacks Investment Research ©